New paper from India [1].
"Outcomes and toxicity of oral Fosfestrol in metastatic castration-resistant prostate cancer-a real-world experience"
This brought back memories of being in groups shortly after I was diagnosed. There were men who discussed where to obtain Honvan (Forfestrol) a DES (Diethylstilbestrol) prodrug - usually Mexico. Some cut the pills up & managed to control progression with quite low doses. (These days, India may be a better bet than Mexico.)
The study was on men with metastatic CRPC.
"At the end of a median follow-up of 16 months, the median progression-free survival (PFS) was 8.3 months (CI 4.7-11.8) and the median overall survival (OS) was 27.5 months (CI 25.4-29.5)."
however, "patients who ... received prior abiraterone acetate therapy had worse survival outcomes."
A significant attraction of oral Honvan is that it is cheap.
It would be interesting to see how BAT + Honvan might improve survival in metastatic CRPC. (Testosterone cypioanate is also inexpensive.)
-Patrick
Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer
BLUE SKY NEWS - AUGUST 2022
